Plus: New capital for CytoReason, Truvian and Renalys

Plus Autobahn heads for treatment-resistant depression with $32M round and updates on Amylyx, Reata, Integral Molecular and more 

Plus Imara to terminate all assets and lay off 83% of employees, and updates from Koelis, BeiGene and more

Investor confidence had run high in Imara, but twin failures dash hopes for lead asset

Bain Capital Life Sciences makes first big splash from new $1.9B third fund

Pharma spinouts account for small percentage of total newcos, but large share of capital raised